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Progressive supranuclear palsy (PSP) is a movement
disorder characterized by tau neuropathology where
the underlying mechanism is unknown. An SNP
(rs1768208 C/T) has been identified as a strong risk
factor for PSP. Here, we identified a much higher
T-allele occurrence and increased levels of the pro-
apoptotic protein appoptosin in PSP patients. Eleva-
tions in appoptosin correlate with activated cas-
pase-3 and caspase-cleaved tau levels. Appoptosin
overexpression increased caspase-mediated tau
cleavage, tau aggregation, and synaptic dysfunction,
whereas appoptosin deficiency reduced tau cleav-
age and aggregation. Appoptosin transduction im-
paired multiple motor functions and exacerbated
neuropathology in tau-transgenic mice in a manner
dependent on caspase-3 and tau. Increased appop-
tosin and caspase-3-cleaved tau were also observed
in brain samples of patients with Alzheimer’s disease
and frontotemporal dementia with tau inclusions.
Our findings reveal a novel role for appoptosin in
neurological disorders with tau neuropathology, link-
ing caspase-3-mediated tau cleavage to synaptic
dysfunction and behavioral/motor defects.
INTRODUCTION
Progressive supranuclear palsy (PSP) is an age-related neurode-
generative disorder characterized by postural instability, vertical
supranuclear gaze palsy, frequent falls, and progressive axial
rigidity (Steele et al., 1964). Neuropathologically, PSP patientsdevelop neurofibrillary tangles (NFTs) that are comprised of
abnormally hyperphosporylated/aggregated tau protein, gliosis,
and neuronal loss mainly in the basal ganglia (especially within
the globus pallidus region), brainstem, frontal cortex, and den-
tate nucleuswithin the cerebellum (Williams and Lees, 2009; Sta-
melou et al., 2010). As a tauopathic disorder, PSP manifests
similar tau pathology with other neurological disorders, such as
Alzheimer’s disease (AD), tauopathic frontotemporal dementia
(FTD-T), and frontotemporal dementia with parkinsonism-17
(FTDP-17). Consistent with the pathological tau abnormalities
observed, genetic studies have suggested that tau is linked to
PSP pathogenesis. Several regional alterations and mutations
in theMAPT gene that encodes tau are associated with PSP sus-
ceptibility (Baker et al., 1999; Conrad et al., 1997; Höglinger
et al., 2011; Pastor et al., 2001; Poorkaj et al., 2002; Rohrer
et al., 2011; Ros et al., 2005; Rossi et al., 2004; Stanford et al.,
2000).
As a microtubule-associated binding protein, tau modulates
microtubule stability in neurons (Drechsel et al., 1992). Overex-
pression of disease-linked tau mutants induces neuronal cell
death and behavioral abnormalities in mice (Ikeda et al., 2005;
Lewis et al., 2000; Tanemura et al., 2001; Yoshiyama et al.,
2007). While amyloid-b (Ab) is regarded as the major component
driving a cascade of pathogenic events leading to AD (Hardy and
Selkoe, 2002), tau is found to be required for Ab-induced post-
synaptic dysfunction and behavioral defects (Ittner et al., 2010;
Roberson et al., 2007; Shipton et al., 2011). Tau hyperphosphor-
ylation and aggregation has widely been shown to interfere with
normal tau function, thus leading to neurodegeneration (Balla-
tore et al., 2007). Recent evidence, however, suggests that cas-
pase-3 can cleave tau at the C terminus, thereby rendering cas-
pase-cleaved/truncated tau to aggregate and rapidly form NFTs
(Ding et al., 2006; Fasulo et al., 2000; Gamblin et al., 2003; Man-
delkow et al., 2007; Rissman et al., 2004). Caspase activation
and caspase-mediated tau cleavage have been viewed as earlyNeuron 87, 963–975, September 2, 2015 ª2015 Elsevier Inc. 963
pathological events triggering NFT pathology, rather than a ter-
minal event that acutely kills neurons (de Calignon et al., 2010;
Gamblin et al., 2003; Rissman et al., 2004). Further, caspase-3
activation impairs synaptic function through the reduction of
dendritic spines and postsynaptic glutamate receptors (D’Ame-
lio et al., 2011). However, whether caspase activation, caspase-
dependent tau cleavage, and other related genetic factors may
be involved in initiating PSP remains largely elusive.
A recent genome-wide association study (GWAS) reported
several new PSP risk loci (Höglinger et al., 2011). Interestingly, a
PSP-associated SNP rs1768208 (C/T) located near the MOBP
gene in chromosome 3 correlated more tightly with expression
of the SLC25A38/Appoptosin gene locus 70 kb away, with
relatively little correlation to MOBP expression (Höglinger et al.,
2011; Zhang et al., 2012). We previously identified appoptosin
as a novel pro-apoptotic protein that inducescaspase-dependent
apoptosis through the intrinsic apoptosis pathway (Zhang et al.,
2012). Appoptosin is a mitochondrial carrier protein whose pro-
posed physiological function is to transport/exchange glycine/
5-amino-levulinic acid across the mitochondrial membrane for
heme synthesis (Guernsey et al., 2009; Zhang et al., 2012).
We showed that upregulation of appoptosin results in cellular
apoptosis, whereas downregulation of appoptosin prevents cell
death and caspase activation caused by neurotoxic insults such
as b-amyloid (Ab) and glutamate (Zhang et al., 2012). These re-
sults reveal appoptosin to be a crucial pro-apoptotic protein
involved in neurodegeneration. However, it remains to be deter-
mined whether appoptosin is involved in the pathogenic develop-
ment of PSP and other neurological disorders.
RESULTS
APSP-Associated T-Allele at SNP rs1768208Associates
with Increased Appoptosin Expression
To investigate the potential role of appoptosin in PSP, we deter-
mined SNP rs1768208 (C/T) genotypes from PSP and control
patient postmortem brain samples (tissue information in Table
S1) by TaqManSNPgenotyping assays.Consistentwith previous
GWASresults (Höglinger et al., 2011), theminorT-allele frequency
in PSP cases was much higher compared to non-PSP controls
(0.44 versus 0.18) (Figure 1A). We identified at least one T-allele
in77%PSPcases tested,while theT-alleleoccurrence incontrols
was found to bemuch lower at 32% (Figure 1B). Since GWASan-
alyses previously showed that appoptosin expression is associ-
ated with SNP rs1768208 (Höglinger et al., 2011), we examined
both mRNA and protein levels of appoptosin and MOBP in these
samples by real-time PCR and western blot, respectively. Our
results showed that both appoptosin mRNA and protein levels
increased in the frontal cortex of PSP patients compared to
controls (Figures 1C and 1D). Immunohistochemistry analysis
also consistently revealed more appoptosin-positive cells in
PSP samples compared to controls (Figure 1E). In contrast, we
found no significant change of MOBP mRNA levels in PSP
samples,with a slight decrease inMOBPprotein levels compared
to controls (Figures S1A andS1B). In all PSP and control samples
tested, expression of appoptosin in T-allele samples were higher
compared to non-T-allele samples (Figure 1F). Conversely,
MOBP expression did not associate with T-allele occurrence964 Neuron 87, 963–975, September 2, 2015 ª2015 Elsevier Inc.(Figure S1C). These results not only corroborate the association
of SNP rs1768208 with PSP, but also clearly establish a correla-
tion between appoptosin expression, PSP, and the T-allele.
Increased Appoptosin Levels Positively Correlate with
Caspase-3 Activation and Caspase-3-Mediated Tau
Cleavage
Caspase-3 activation has been observed in multiple chronic
neurodegenerative disorders including AD, Parkinson’s disease
(PD), FTD-T, and Huntington’s disease (HD) (D’Amelio et al.,
2012). We also observed increased levels of cleaved caspase-3
(an active form of caspase-3, c-caspase-3) in the frontal cortex
of PSP brains (Figures 1D and 1E). Activated caspase-3 cleaves
tau at Asp421, and the consequent tau fragment (c-tau) level
was previously found to be elevated in AD brain tissues (Fasulo
et al., 2000; Gamblin et al., 2003; Rissman et al., 2004). We de-
tected a marked increase in levels of c-tau, but not tau, from
PSP cortical brain tissue relative to controls by western blot (Fig-
ure 1D) and immunohistochemistry (Figure 1E). In addition, we
observed clear c-tau and appoptosin staining in various brain re-
gions including the entorhinal cortex, cerebellum, pons, striatum,
and substantia nigra but rarely in the amygdala and inferior parie-
tal cortex of PSPpatients (Figure S1D). The staining of appoptosin
was rarely found in astrocytes and microglia, as observed by
GFAP and Iba1 staining, respectively (Figure S1E). Appoptosin
levels positively correlated with both c-caspase-3 (Figure 1G)
and c-tau (Figure 1H). We also observed a dramatic increase in
hyperphosphorylated PHF-1 levels from PSP brain samples (Fig-
ures 1D and 1E). Co-localization of appoptosin with c-tau, c-cas-
pase-3, and PHF1, respectively, aswell as co-localization of c-tau
with phosphorylated tauwas observed in the frontal cortex of PSP
individuals (Figures 1E, S1E, and S1F). Interestingly, the expres-
sion of PHF-1 in T-allele PSP samples was significantly higher
compared to PSP samples without the T-allele (Figure S1G), sug-
gesting a strong correlation between T-allele occurrence and
pathological severity in PSP patients.
Appoptosin Regulates Tau Cleavage via Caspase-3
Activation
To ascertain whether upregulation of appoptosin leads to tau
cleavage, we transduced primary rat cortical neuronal cultures
with adenoviruses expressing human appoptosin. Terminal de-
oxynucleotidyl transferase dUTP nick end labeling (TUNEL) as-
says showed that overexpression of human appoptosin did not
induce significant neuronal death until 9 days after transduction
(Figure S2A), despite detection of caspase activation 2 days after
transduction (data not shown). Although this differs from our pre-
vious observations in dividing cells such as HEK293 and HeLa
cells, which exhibit cell death as early as 1 day after appoptosin
overexpression, it is consistent with a recent postulation that the
post-mitotic neurons respond to caspase-mediated apoptosis
differently from non-neuronal cells (D’Amelio et al., 2012; Hyman
and Yuan, 2012). For example, disease-linked tau mutations in
mice can cause caspase activation prior to NFT formation
without inducing neuronal death for at least 5 days (de Calignon
et al., 2010). Interestingly, we found that overexpression of ap-
poptosin increased susceptibility of neurons to apoptosis
induced by Ab and MPP+ insults (Figure S2B). With a 6-day
Figure 1. Elevated Appoptosin Levels Asso-
ciatewithHigher T-Allele Occurrence at SNP
rs1768208 andCorrelatewith IncreasedCas-
pase-3 Activation and Tau Cleavage in PSP
Brains
(A and B) The frequency (A) and occurrence (B)
of the minor T-allele at SNP rs1768208 (C/T) in
control and PSP patients. T occurrence: number of
cases with T-allele/number of total cases (Control,
n = 22; PSP, n = 26). Odds ratio is calculated with R
statistical software.
(C) Relative appoptosinmRNA levels in control and
PSP brain samples (Control, n = 15; PSP, n = 23).
(D) Western blot analysis of appoptosin, c-cas-
pase-3, c-tau, PHF-1, and tau levels in the frontal
cortex of PSP and control individuals (Control, n =
15; PSP, n = 23).
(E) Immunohistochemistry analysis of appoptosin,
c-caspase-3, c-tau and PHF-1 in the cortex of
PSP and control individuals (n = 4). Scale bar,
100 mm. Red arrows indicate some of the cells
double stained appoptosin and c-tau in adjacent
sections.
(F) Relative appoptosin protein levels in SNP
rs1768208 T-allele carriers and non-T-allele (C)
carriers (n = 19 per group).
(G and H) The correlation between c-caspase-3
and appoptosin (G) and between c-tau and ap-
poptosin (H) protein levels (regression analysis,
n = 38).
Data represent mean ± SD. *p < 0.05, **p < 0.01,
****p < 0.0001 by nonparametric t test. See also
Figure S1.transduction period for all following experiments, we found that
both c-caspase-3 and c-tau, but not tau, levels were dramati-
cally increased with appoptosin overexpression (Figure 2A).
Conversely, appoptosin deficiency resulted in a significant
reduction of c-caspase-3 and c-tau levels (Figures 2B, S2C,
and S2D). Appoptosin transduction-dependent c-tau elevation
was completely abolished with the application of caspase-3 or
caspase-9 inhibitors (Figure 2C). Furthermore, caspase activa-
tion by appoptosin overexpression failed to cleave a caspase-re-
fractory mutant tau (D421A) (where the consensus caspase-3
recognition site D421 was mutated) (Fasulo et al., 2000; Gamblin
et al., 2003; Rissman et al., 2004) (Figure S2E). These results indi-
cate that appoptosin-induced tau cleavage is indeed mediated
by caspase-3/9 activation.Neuron 87, 963–975, SAppoptosin Affects Microtubule-
Binding Ability and Aggregation
of Tau
To determine whether appoptosin over-
expression and subsequent tau cleavage
can affect tau microtubule-binding and
tau aggregation, we first determined
appoptosin-dependent effects on tau
microtubule-binding (Vogelsberg-Raga-
glia et al., 2000; Waxman and Giasson
2011). Appoptosin overexpression atten-uated tau association with microtubules and c-tau was found
mostly associated with non-microtubule fractions (Figure 3A).
Moreover, the caspase-3 inhibitor C3I abolished caspase-3
cleavage and re-established tau microtubule binding with ap-
poptosin overexpression (Figure 3A). Using a filter/trap assay
to measure tau aggregation (Dou et al., 2003; Zhang et al.,
2006), we found that appoptosin overexpression increased
levels of SDS-insoluble tau aggregates with little effect on total
levels of SDS-soluble tau (Figure 3B). Although full-length tau
is primarily localized in the axon (Ballatore et al., 2007), we
observed numerous neuronal c-tau puncta in MAP2-positive
dendrites with appoptosin overexpression using an adeno-asso-
ciated virus (AAV) expression system (Figure 3C). Conversely,
the amount of c-tau puncta in MAP2-positive dendrites waseptember 2, 2015 ª2015 Elsevier Inc. 965
Figure 2. Appoptosin Regulates Tau Cleavage through Caspase-3
Activation
(A) Change in c-caspase-3, c-tau, and tau levels in neuronal cultures following
appoptosin transduction as determined by western blot (n = 3 per group, two-
tailed Student’s t test).
(B) Western blot analysis of c-tau, c-caspase3, tau, and PSD95 in cortical
neuronal cultures from appoptosin knockout mouse embryos or littermate
controls (n = 3 per group, two-tailed Student’s t test).
(C) Change in c-tau and cleaved-PARP (c-PARP) levels in neuronal cultures
after appoptosin overexpression and exposure to DMSO, caspase-3 inhibitor
(C3I), or caspase-9 inhibitor (C9I) (n = 3 per group, repeated-measures one-
way ANOVA with Dunnett’s post hoc analysis).
Data represent mean ± SD. *p < 0.05, **p < 0.01, and #p < 0.05. See also
Figure S2.reduced in cortical neurons derived from appoptosin knockout
(KO) embryos (Figure 3D). We also observed c-tau puncta in
MAP2-negative neurites, which likely represents axonal tau/c-
tau or tau/c-tau aggregates.
Appoptosin Overexpression Disrupts Synaptic
Structures and Decreases Levels of Cell Surface
Glutamate Receptors
Hyperphosphorylated tau canbemis-sorted intodendritic spines
to consequently disrupt synaptic function (Hoover et al., 2010).966 Neuron 87, 963–975, September 2, 2015 ª2015 Elsevier Inc.Although a large amount of endogenous c-tau appears to
localize to dendrites (Figure 3C), it is unclear at this point whether
synaptic c-tau can cause degenerative effects. To address this,
we carried out fractionation assays (Wang et al., 2013) and
observed the presence of c-tau and c-caspase-3 in both synap-
tosomal and postsynaptic density (PSD) fractions (Figure 4A).
Full-length tau was also found in synaptosomal fractions, with
relatively little partitioning to PSD fractions (Figure 4A). c-Tau
levels were markedly increased in all fractions assayed upon
appoptosin overexpression, and this increase was enhanced in
synaptosomal and PSD fractions (Figure 4A). Additionally, over-
expression of appoptosin decreased the number of spines and
synapsin-I/PSD95 merged clusters. These appoptosin-depen-
dent synapototoxic effects were inhibited with the application
of caspase-3 inhibitors and absent in tau-deficient neurons
(Figures 4B, 4C, and S3A). These results show that appoptosin
overexpression disrupts synaptic structures. It is also possible
that appoptosin overexpression may prevent spine/synapse
development in these cultured primary neurons, which deserves
further scrutiny. Moreover, cell surface biotinylation experiments
showed reduced cell surface levels of various ionotropic AMPA
receptor and NMDA receptor subunits, including GluR1, GluR2,
NR1, NR2A, and NR2B in neurons overexpressing appoptosin
(Figure 4D). Notably, the reduction of GluR1 and NR1 resulting
from appoptosin overexpression was reversed by caspase-3 in-
hibition; and appoptosin ovexpression failed to affect cell surface
levels of GluR1 and NR1 in tau-deficient neurons (Figures S3B
and S3C). These findings suggest that upregulation of appopto-
sin may disrupt synaptic structures by activating caspase-3/tau
cleavage.
Overexpression of Appopotosin Induces Motor Deficits
and Aggravates Tau Pathology in Tau Transgenic Mice
To investigate the pathogenic role of appoptosin in vivo, we
stereotaxically injected AAV particles expressing appoptosin
or GFP alone (as control) into the globus pallidus of 6-
month-old JNPL3 tau transgenic mice carrying an FTDP-17
human P301L mutant tau allele (Figure 5A) (Lewis et al.,
2000). Behavioral attributes were assayed 2 months after in-
jection. Human appoptosin transduction (resulting in approxi-
mately 3- to 4-fold expression over endogenous levels;
Figure 5B) severely impaired motor function in JNPL3 mice.
Specifically, appoptosin-transduced JNPL3 mice exhibited
shorter stride lengths as determined by catwalk assay com-
pared to controls (Figure 5C), which is a typically character-
istic trait in PSP patients (Egerton et al., 2012). Using acceler-
ating rotarod and balance beam tests, we found that mice
with appoptosin transduction fell much faster from the rotor
after 2 or 4 days of training (Figure 5D), and exhibited in-
creased slip frequency (Figure 5E), compared to control
mice. Appoptosin transduction in another tauopathy mouse
model harboring the FTDP-17 R406W tau mutation (Ikeda
et al., 2005) showed similar impairment on motor functions
in fixed speed rotarod and grip strength tests (Figures S4A
and S4B). We also performed novel object recognition tests
to assess learning and memory and found no differences
between control and appoptosin-overexpressing mice (Fig-
ure S4C). Immunohistochemistry analysis showed that AAV
Figure 3. Overexpression of Appoptosin Reduces Tau Association with Microtubules and Promotes Tau Aggregation
(A) Change in tau found in microtubule-bound and unbound fractions following appoptosin overexpression and treatment with C3I (n = 3 per group, repeated-
measures One-way ANOVA with Dunnett’s post hoc analysis).
(B) Quantification of SDS-insoluble tau aggregates in neuronal cultures following appoptosin transduction as determined by filter/trap assays. SDS-soluble tau
was used as a control (n = 3 per group, two-tailed Student’s t test).
(C) Staining of c-tau andMAP2 in neurons transducedwith AAV-appoptosin or AAV-GFP. Green color represents GFPwithout staining, whichwas used to identify
transduced neurons (n = 15 per group, two-tailed Student’s t test). Scale bar, 20 mm.
(D) c-Tau puncta in dendrites of appoptosin KO or littermate control neurons were detected by immunocytochemistry (n = 15 per group, two-tailed Student’s
t test). Scale bar, 20 mm.
Data represent mean ± SD. *p < 0.05, **p < 0.01, and #p < 0.05.transduction and expression occurs mainly in neurons, and
appoptosin transduction increased immunoreactivity of c-cas-
pase-3, c-tau, and hyperphosphorylated PHF-1 tau in theinjection area (Figures 5F and S4D). We also determined the
expression of appoptosin, c-tau, and PHF1 in both young
(6-month-old) and aged (12-month-old) JNPL3 mice and foundNeuron 87, 963–975, September 2, 2015 ª2015 Elsevier Inc. 967
Figure 4. Overexpression of Appoptosin Promotes c-Tau Distribution to Post-synaptic Compartments, Disrupts Synaptic Structure, and
Depletes Cell Surface Glutamate Receptors
(A) Distribution of c-tau, c-caspase-3, and total tau in postnuclear (S1), synaptosomal (Syn), and PSD fractions after appoptosin overexpression (n = 3 per group,
two-tailed Student’s t test).
(B and C) DIV (days in vitro) 14 neurons were transfected or transduced with AAV-appoptosin. Numbers of dendritic spines (B) and Synapsin-I/PSD95 double-
positive puncta (C) in neuronswith appoptosin overexpression and caspase-3 inhibition (n = 15 per group, one-way ANOVAwith Tukey’s post hoc analysis). Scale
bar, 10 mm.
(D) Cell surface levels of NR1, NR2A, NR2B, GluR1, GluR2, and Na+/K+ATPase (as a control) in neurons with appoptosin overexpression, as determined by cell
surface biotinylation assays (n = 3 per group, two-tailed Student’s t test).
Data represent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and #p < 0.05. See also Figure S3.
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Figure 5. Overexpression of Appopotosin
Causes PSP-like Motor Deficits and In-
duces Tau Pathology
(A) Schematic workflow of stereotaxic AAV injec-
tion into the globus pallidus of JNPL3 mice. LV,
lateral ventricle; CPu, caudate putamen; GP,
globus pallidus.
(B–F) Behavioral and histological analysis of
JNPL3 mice injected with AAV-appoptosin or
AAV-GFP (control).
(B) Confirmation of appoptosin overexpression
within the injected area (n = 8 per group, two-tailed
Student’s t test). Scale bar, 30 mm.
(C) Catwalk analysis: comparison of stride length
of each limb (RF, right front; RH, right hind; LF, left
front; LH, left hind) of experimental mice (n = 8 per
group, two-way ANOVA with Sidak’s post hoc
analysis).
(D) Accelerating rotarod test: latency of experi-
mental mice on the rotor at days after training as
indicated (n = 8 per group, two-way ANOVA with
Sidak’s post hoc analysis).
(E) Number of slips observed in experimental mice
in balance beam tests (n = 8 per group, two-tailed
Student’s t test).
(F) The expression of GFP, c-caspase-3, c-tau,
PHF-1 tau, and tau in the injected area in experi-
mental mice. n = 8, Scale bar, 30 mm.
Data represent mean ± SD. *p < 0.05, **p < 0.01,
and ***p < 0.001. See also Figure S4.an increase in both c-tau and PHF1, but not appoptosin levels
in aged JNPL3 mice (Figures S4E and S4F).
Appoptosin-Mediated Pathogenesis Requires Caspase
Activity and the Presence of Tau
Our results in vitro suggest that caspase-3 is a key mediator of
degeneration in conjuction with appoptosin overexpression. To
further determine the role of caspase-3 in vivo, we infused a
caspase-3 inhibitor into JNPL3 mouse brain using a minipump
system. Catwalk assays show that in the presence of caspase
inhibition, appoptosin-transduced JNPL3 mice displayed nor-
mal stride length similar to control mice (Figure 6A). As ex-
pected, appoptosin transduction failed to increase levels of
c-tau and PHF1 when caspase-3 was inhibited (Figures 6B,
6C, and S4G). Neuronal loss/defects and astrogliosis in appop-
tosin-transduced JNPL3 mice were also rescued by caspase-3
inhibition, as evidenced by NeuN/MAP2 and GFAP immuno-
staining (Figures 6B and 6C).
To determine the involvement of tau in appoptosin-mediated
pathogenesis, we injected AAV-appoptosin into wild-type (WT)
and tau knockout (KO) mice. Appoptosin transduction failed toNeuron 87, 963–975, Saffect gait and balance of tau KO mice
in a round beam test, whereas appopto-
sin transduction significantly impaired
the mobility of WT control mice (Fig-
ure 6D). Although appoptosin trans-
duction consistently produced a slight
increase in caspase-3 activity, it had lit-
tle effect on neuronal loss/defects andastrogliosis in tau KO mice, compared to the WT mice (Fig-
ure 6E). These results further support the involvement of cas-
pase-3 and tau in appoptosin-mediated motor dysfunction and
PSP-associated neuropathology.
Appoptosin Expression Increases in FTD-T and AD
Since appoptosin expression is increased in PSP and upregula-
tion of appoptosin can accelerate neurodegeneration and tau
pathology, we next examined levels of appoptosin in other
neurodegenerative diseases. We surveyed cortical brain tissue
from AD, PD, FTD-T, and HD for comparative changes in appop-
tosin and c-tau levels and observed a selective upregulation of
appoptosin/c-tau in AD and FTD-T, but not in other neurological
disorders lacking apparent tau pathology (Figure 7A).
DISCUSSION
Until now, mechanisms underlying PSP pathogenesis remained
obscure. Although recent studies have begun to identify genetic
factors associated with PSP, little information regarding molecu-
lar mechanism driving onset have been defined (Borroni et al.,eptember 2, 2015 ª2015 Elsevier Inc. 969
(legend on next page)
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Figure 7. Appoptosin Is Upregulated in
Tauopathic Disorders, and Drives Patho-
genesis through Caspase Activation, Tau
Cleavage and Aggregation
(A) Analysis of appoptosin and c-tau expression in
the frontal cortex of AD, PD, control, FTD-T, and
HD individuals (AD, n = 8; PD, n = 3; control, n = 3;
FTD-T, n = 3; HD, n = 3). Data represent mean ±
SD. *p < 0.05, **p < 0.01, ***p < 0.001, two-tailed
Student’s t test.
(B) Appoptosin potentially drives PSP pathogen-
esis through caspase-3 mediated tau cleavage
and NFT formation. Appoptosin expression is
increased in PSP individuals through a C/T poly-
morphism at the SNP rs1768208 or stress.
Increased appoptosin protein increases heme
synthesis and thus activates the intrinsic caspase
pathway and caspase-mediated tau cleavage.
Cleaved tau (c-tau) is prone to aggregate to form
neurofibrillary tangles (NFT), which is deleterious
to neurons. c-Tau also can be mis-sorted into the
postsynaptic compartment to trigger synaptic
dysfunction. Together with caspase activation,
these events eventually lead to tau pathology and
neurodegeneration in PSP.2011; Höglinger et al., 2011). Herein, our studies reveal a high T-
allele occurrence of 77% at rs1768208 among PSP patients (Fig-
ure 1B); this high T-allele occurrence in PSP surpasses the ApoE4
occurrence found in40%–60% among AD patients (Ward et al.,
2012), suggesting that this rs1768208SNPwith T-allele is a strong
risk factor for PSPandmay serve as a diagnostic biomarker.More
importantly, T-allele occurrence correlates with appoptosin pro-Figure 6. Caspase Inhibition and Tau Knockout Reduces Detrimental Effect Caused by Appop
(A–C) Behavioral and histological analysis of JNPL3 mice injected with AAV-appoptosin or AAV-GFP (contro
(A) Comparison of stride length of each limb (RF, right front; RH, right hind; LF, left front; LH, left hind) of experim
Tukey’s post hoc analysis).
(B) Immunostaining to show expression of c-Tau, PHF1, NeuN, GFAP, and MAP2 in the infection area.
(C) Quantification of immunostaining from JNPL3 mice (n = 8 per group, one-way ANOVA with Dunnett’s po
(D and E) Behavioral and histological analysis of wild-type (WT) mice and tau knockout (KO) mice injected w
(D) Number of errors made by experimental mice during the round beam test (n = 12 for WT and Tau KO mice
appoptosin mice, two-way ANOVA with Sidak’s post hoc analysis).
(E) Expression of NeuN, GFAP, MAP2, and c-caspase-3 in the injection area (n = 11 forWT and Tau KO-appop
Tau KO mice, two-way ANOVA with Sidak’s post hoc analysis). Scale bar, 50 mm.
Data represent mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S4G.
Neuron 87, 963–975, Stein levels (Figure 1F). We also show that
a majority of PSP individuals exhibit
increased appoptosin and c-tau levels
and further demonstrate that appoptosin
upregulation activates caspase-3 and
consequent tau cleavage. Tau cleavage
consequently triggers tau aggregation,
impairment in synaptic structures and
glutamate receptor trafficking, and behav-
ioral motor capacity and tau pathology in
tau transgenic mice. In addition to genetic
factors, mitochondrial dysfunction and
oxidative stress are also linked to PSP
(Stamelou et al., 2010). An excessive levelof appoptosin is known to collapse mitochondrial membrane po-
tential, thereby releasing reactive oxygen species (ROS) and sub-
jecting cells to oxidative insult (Zhang et al., 2012). Although
further studies may be needed to dissect the contribution of ap-
poptosin-induced ROS and related oxidative pathways in the
pathogenesis of PSP, we rationalize that elevated appoptosin
expression induced by genetic or stress factors in PSP-vulnerabletosin Overexpression
l) and treated with or without caspase-3 inhibitor.
ental mice (n = 11 per group, two-way ANOVAwith
st hoc analysis).
ith AAV-appoptosin or AAV-GFP.
, n = 9 for WT-appoptosin mice, n = 11 for Tau KO-
tosinmice, n = 9 forWT-appoptosinmice, n = 10 for
eptember 2, 2015 ª2015 Elsevier Inc. 971
brain regions leads to caspase-3 activation and subsequent tau
cleavage, thereby progressively accumulating neurodegenerative
defects in human PSP cases (see Figure 7B for the schematic
model).
Caspase activation is observed in several chronic neurodegen-
erative diseases includingAD, FTD-T,HD, andPD (D’Amelio et al.,
2012). We also observed caspase-3 activation in PSP (Figures 1D
and 1E). Although caspase activation presumptively triggers to
rapid cell death, a recent study reported that caspase activation
induced NFT formation with a failure to cause acute neuronal
cell death in a P301L tauopathic transgenicmousemodel (de Cal-
ignon et al., 2010). Supporting this notion, we show that over-
expression of appoptosin in neuronal cultures rapidly activates
caspase-3 but does not cause acute cell death (Figure S2A).
Although it is currently unclear why neurons with activated cas-
pase-3cansurvive for several days, activatedcaspase-3maypro-
gressively impair neuronal structure and function. For example,
caspase-3 activation is found to induce spine loss and memory
deficits in Tg2576 AD mice as early as 3 months (D’Amelio et al.,
2011).We show that upregulation of appoptosin disrupts synaptic
structures and reduces cell surface glutamate receptors, while
caspase inhibition can partially rescue these phenotypes (Figures
4B–4D and S3B). Caspase inhibition also ameliorates neuropath-
ological changes resulting from appoptosin overexpression in tau
transgenicJNPL3mice (Figures6Band6C).Taken together, these
findings suggest that caspases play a pivotal role in appoptosin-
induced neurodegeneration and that caspase inhibition may be
a potential target in the treatment of neurodegenerative disorders
in instanceswhere interferencewith caspase-dependent synaptic
function is less consequential in comparison to overall ameliora-
tive effects in disease onset with caspase inhibition.
Itwaspreviously shown that tauplays anessential role inAb-in-
duced behavioral deficits, dendritic and axonal abnormalities in
AD mouse models, and neuronal cultures (Ittner et al., 2010;
Roberson et al., 2007; Stancu et al., 2014; Vossel et al., 2010).
To this point, it was unclear which form(s) of tau may be pivotal
in driving these processes. Classically, tau hyperphosphorylation
is considered to be essential in NFT formation and neurodegen-
eration (Mazanetz and Fischer, 2007). However, recent evidence
indicates that caspase-cleaved tau is more prone to form aggre-
gates/fibrils and may therefore also be imperative to the patho-
genesis of tauopathies (Ding et al., 2006; Fasulo et al., 2000;
Gamblin et al., 2003; Mandelkow et al., 2007; Rissman et al.,
2004). We previously demonstrated that Ab exposure increased
appoptosin expression and downregulation of appoptosin pro-
tects neurons against Ab-induced mitochondria fragmentation
and cell death (Zhang et al., 2012). Herein, we show that overex-
pression of appoptosin can promote tau-cleavage by activating
caspase-3. In addition, tau deficiency significantly ameliorates
motor defects and neuropathology caused by appoptosin over-
expression. These results suggest that tau plays a key role in ap-
poptosin-mediated neurodegeneration. Since c-tau is enriched
in synaptosomesandPSDcompartments uponappoptosin over-
expression (Figure 4A) and can inducemitochondrial dysfunction
and apoptosis in neurons (Fasulo et al., 2005; Quintanilla et al.,
2009), c-tau may be a processed tau species which contributes
to early synaptic impairment and eventual neuronal cell death in
response to Ab exposure or appoptosin overexpression. More-972 Neuron 87, 963–975, September 2, 2015 ª2015 Elsevier Inc.over, tau KO neurons are resistant to appopotosin-induced
defects in spine/cell surface glutamate receptor levels, further
emphasizing the role of c-tau in neurotoxicity. Further studies
characterizing the relationship between Ab/appoptosin/c-tau
and synaptic degeneration/mitochondrial dysfunction/apoptosis
would bemeaningful in elucidatingmechanismsdriving neurode-
generation in AD and PSP.
Our results demonstrate increased c-tau and appoptosin levels
in PSP, AD, and FTD-T (Figures 1 and 7A). In addition to its asso-
ciation with PSP, the rs1768208 T-allele SNP was also recently
found to be associated with the ApoE4 allele and shown to be
linked with the development of FTD-tau pathology (Liu et al.,
2013; McMillan et al., 2014). Moreover, appoptosin expression
is sensitive to various neurotoxic and stress conditions (Zhang
et al., 2012). Disease-associated factors such as Ab, APOE4,
tau, environmental factors, aging, and increased appoptosin
expression may interact with each other during the pathological
development of various neurological disorders. We hypothesize
that appoptosin may be a common mediator rendering neurons
more susceptible to caspase-mediated toxicity through cleavage
of components such as c-tau. Elucidation of the molecular path-
ways mediated by appoptosin in various tauopathies will help
identify new therapeutic targets for these devastating diseases.
EXPERIMENTAL PROCEDURES
Mice
Human mutant tau (P301L) transgenic (Tg) JNPL3 mice were obtained from
Taconic. Human mutant tau (R406W) Tg mice were generated and maintained
as described previously (Ikeda et al., 2005). Tau knockout (KO) mice
were obtained from Jackson Lab. Appoptosin KO mice were generated
as described in the Supplemental Experimental Procedures. Bothmale and fe-
male JNPL3 mice were characterized, while only Tau (R406W) Tg and Tau KO
males were used for experiment described. Experimental mice were primarily
selected from matching litters. All experiments involving animals were per-
formed under the guidelines of the Sanford Burnham Prebys Medical Discov-
ery Institute Institutional Animal Care and Use Committee.
Human Brain Specimens
Human brain samples were obtained from University of California San Diego;
Toronto General Hospital, University of Toronto, Canada; and the Brain and
Tissue Bank for Developmental Disorders, University of Maryland in Baltimore,
in contract with the National Institutes of Health, National Institute of Child
Health and Human Development. All human brain samples were analyzed
with institutional permission under California and National Institutes of Health
guidelines. For specimen information, see Table S1.
SNP Analysis
Genomic DNA (gDNA) was extracted using conventional methods, as des-
cribed previously (Blin and Stafford, 1976), from postmortem PSP and control
patient brains with clinical characterization. rs1768208 SNP analysis was per-
formed using an Allelic Discrimination Assay developed by Applied Bio-
systems. Briefly, equal amounts of gDNA from each sample were subjected
to real-time PCR amplification using a TaqMan SNP Genotyping Assay Mix
specifically designed for rs1768208 (Assay ID: C____75367_10, Life Technol-
ogies), and TaqMan Universal PCRMaster Mix (Life Technologies). PCR reac-
tions and endpoint measurements were recorded and subsequently analyzed
using an Applied Biosystems 7900HT Fast Real-Time PCR system.
Cell Culture, Transduction, and Transfection
Primary cortical neuronal cultures were prepared from embryonic day 18.5
(E18.5) rats or E15.5 mice. Neuronal cultures were transduced with Ad-appop-
tosin/AAV-appoptosin or control adenovirus/AAV-GFP for Western blot and
immunocytochemistry. For spine analysis, DIV 14 neurons were transfected
with AAV-GFP or AAV-appopotsin plasmid vectors using Lipofectamine
2000 (Life Technologies). HEK293T cells were transfected with indicated plas-
mids using Turbofect (Thermo Scientific). For details and information regarding
constructs and viruses, refer to Supplemental Experimental Procedures.
Western Blot
Cells or human brain tissues were lysed in a lysis buffer (25 mM Tris-HCl [pH
7.6], 150 mM sodium chloride, 1% sodium deoxycholate, 1% Nonidet P-40,
0.1% sodium dodecyl sulfate [SDS]), supplemented with the Complete prote-
ase inhibitor cocktail (Roche), followed by sonication and centrifugation. Equal
protein quantities derived from cell lysates were subjected to SDS-polyacryl-
amide gel electrophoresis and probed by antibodies indicated; specifically,
the anti-human appoptosin (anti-SLC25A38) rabbit monoclonal antibody (Ab-
cam, ab133614, Epitomics Cat# 5566-1 RRID: AB_11000456) was developed
in collaboration with Epitomics (more information regarding antibodies can be
found in Supplemental Experimental Procedures).
Filter/Trap Assays for Tau Aggregates
Filter/trap assays were carried out according to a previously described proto-
col (Dou et al., 2003; Zhang et al., 2006). Briefly, neurons were lysed in a buffer
containing 0.5% Nonidet P-40/1 mM EDTA/50 mM Tris$HCl (pH 8.0)/120 mM
NaCl/with a protease inhibitors cocktail. After brief sonication, the lysates were
passed through a cellulose acetate membrane (0.2 mm; Bio-Rad) using a Bio-
Dot Microfiltration Apparatus (Bio-Rad), washed three times with or without
1%SDS, followed by immunoblotting using a tau antibody (Santa Cruz). Quan-
titative western blot analysis was used to determine levels of tau aggregates in
each sample.
Microtubule-Binding Assay
Microtubule-binding assays were performed as previously described (Vogels-
berg-Ragaglia et al., 2000; Waxman and Giasson 2011). Briefly, neurons were
homogenized with pre-warmed 100 mM MES (pH 6.8), 1 mM EGTA, 0.5 mM
MgSO4, 2 mM DTT, 0.75 M NaCl, 20 mM NaF, 0.1% Triton X-100, 20 mM
taxol, 2 mM GTP, and protease inhibitors at 37C. The homogenates were
centrifuged at 50,000 3 g for 20 min to separate the supernatant containing
non-microtubule bound protein from the pellet (microtubule bound fraction).
Samples were then subjected to western blot analysis.
Preparation of Synaptosomal and PSD Fractions
Synaptosomal and PSD fractions were prepared as previously described
(Wang et al., 2013). See details in Supplemental Experimental Procedures.
Cell Surface Biotinylation Assay
Biotinylation was performed as previously described (Zhao et al., 2012).
Briefly, neurons were washed with ice-cold PBS containing 1 mM each of
CaCl2 and MgCl2 and incubated at 4
C with 0.5 mg/ml Sulfo-NHS-LC-biotin
(Pierce) for 20 min; biotin-labeling was repeated for an additional 20 min. Cells
were then lysed in lysis buffer without SDS, and lysates were affinity-precipi-
tated with streptavidin-agarose beads (Pierce). Biotinylated proteins were
subjected to western blot analysis.
Stereotactic Injection
Recombinant human appoptosin and GFP AAV (2 ml, titer 13 1013) were ster-
eotactically injected into the Globus pallidus of tau Tg mice (6 month old), and
tau KO and WT mice (10 month old) at the following coordinates: anterior
posterior, 0.4 mm; medial lateral, ± 1.7 mm; dorsal ventral, 3.5 mm. Two
months after injection, mice were used for behavioral tests and subsequently
sacrificed for immunohistological analyses. To inhibit caspase-3, DMSO or Z-
DEVD-FMK (BD Biosciences) were pumped into mice injected AAV-appopto-
sin or AAV-GFP (see details in Supplemental Experimental Procedures).
Immunocytochemistry
For spine analysis, neurons were fixed in 4% paraformaldehyde (PFA) and
subsequently mounted for microscopic analysis. For all other experiments,
treated neurons were fixed in 4% PFA, permeabilized, and blocked in 5%
bovine serum albumin. Neurons were incubated with indicated primary anti-bodies at 4C overnight. Cells were then incubated with fluorescence-conju-
gated secondary antibodies. Specimens were examined under a Decon mi-
croscope (Axio Observer Z1, ZEISS).
Immunohistochemistry
Mice were anesthetized and fixed by cardiac perfusion with 4% PFA in PBS.
Tissues were embedded in paraffin for sectioning. For Tau KO experiments,
tissues were subjected to free-floating sectioning after fixation (40 mm). Coro-
nal brain sections (5 mm) were deparaffinized, hydrated, and immunostained
with indicated antibodies. After additional incubation with a biotinylated sec-
ondary antibody, samples were incubated in ABC Elite (HRP) reagent (Vector
Laboratories). Reactions were developed using a DAB substrate (Vector Lab-
oratories). All samples were visualized under a light microscope.
Behavioral Tests
Experimental mice injected with AAV-GFP or AAV-appoptosin were subjected
to gait analysis, rotarod test, balance beam test, round beam test, grip test,
and novel object test. See details in Supplemental Experimental Procedures.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism or R. Differences
between two means were assessed by paired or unpaired t tests. Differences
among multiple means were assessed by ANOVAs. All data are presented as
mean ± SD. Null hypotheses were rejected at p > 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2015.08.020.
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